Azitra (AZTR)
Develops engineered skin bacteria and proteins for dermatology, cosmetic ingredients, and biotechnology tools.
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update.
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient Ex vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin BRANFORD, Conn.
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond.
Azitra, Inc. to Present at 2026 BIO International Convention
/PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
BRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally scheduled for and convened on June 4, 2026, has been adjourned until June 15, 2026, at 11:00 a.m.
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
BRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting") scheduled for June 4, 2026 at 11:00 a.m.
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update.
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the treatment of Netherton syndrome BRANFORD, Conn.
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Preclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studies BRANFORD, Conn., April 28, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the presentation of new preclinical data from its ATR-01 program at the 2026 Annual Meeting of the American Society of Gene & Cell Therapy ("ASGCT 2026").
Why Are Shares Of Azitra Rising?
Azitra's spike is being fueled by a securities purchase agreement with healthcare-focused institutional investors for gross proceeds of up to $31.4 million, with Series B and C warrants exercisable at $0.123 per share and Series A convertible preferred priced at $1,000 per share.
Azitra Inc. (AZTR) Surges Over 44% After Hours— Here's Why It's Trending
Azitra shares jumped over 44% in after-hours trading following a $31.4 million financing deal to advance its filaggrin protein and peptide platform.
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Initial funding of approximately $10.5MM in convertible preferred stock and up to an additional $20.9MM upon cash exercise of warrants Financing marks launch of Azitra new innovative protein and peptide research programs for the cosmetic and cosmeceutical markets Leverages untapped potential of Azitra's genetic engineering platform to accelerate time to commercialization BRANFORD, Conn., March 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement (the "SPA") with new and existing healthcare focused institutional investors.
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide").
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026.
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update.
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484).
Azitra, Inc. to Present at BIO Investment & Growth Summit
BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026.
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for and convened on February 6, 2026, (the "Special Meeting") has been adjourned until March 6, 2026, at 11:00 a.m.
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
BRANFORD, Conn., Jan. 7, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at Biotech Showcase™ taking place in San Francisco, January 12-14, 2026.